Nymox Pharmaceutical (NYMX) Announces First Patient Enrollment for NX02-0022 Reinjection Study of NX-1207 for BPH
4/23/2013 11:17:40 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
HASBROUCK HEIGHTS, N.J., April 23, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that the first patient has been enrolled in the Company's Study NX02-0022. The NX02-0022 Study is designed as an open label study of the safety and efficacy of NX-1207 reinjection for the treatment of prostate enlargement (benign prostatic hyperplasia or BPH). The new study will enroll 100-200 subjects who had previously participated in an NX-1207 BPH study and will involve a second treatment of intraprostatic NX-1207 2.5 mg.
Help employers find you! Check out all the jobs and post your resume.